Comparison · NCT06476366-c795886e
Methotrexate Arm vs Azathioprine: 50% Reduction in the Eczema Area and Severity Index Score (EASI-50)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Methotrexate Arm vs Azathioprine: 50% Reduction in the Eczema Area and Severity Index Score (EASI-50). Trial comparisons, record NCT06476366-c795886e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06476366-c795886e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.375 | 0.137 | 0.694 | wilson | |
| Risk in group 2 | 0.286 | 0.0822 | 0.641 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0893 | -0.338 | 0.468 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.31 | 0.301 | 5.73 | log | |
| Odds ratio, group 1 over group 2 | 1.5 | 0.17 | 13.2 | log | |
| Number needed to treat, for one more participant with the outcome on Methotrexate Arm than on Azathioprine | 11.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Methotrexate Arm | After the enrollment of patients and taking consent, participants will be divided in two treatment groups via lottery method. Group A will be administered oral methotrexate 10mg/week after a test dose | 3 | 8 | OG000 |
| Group 2 | Azathioprine | group B will be administered tablet azathioprine at a dose of 0.3mg/kg daily after. Both group of patients will be advised regarding strict sun protection measures (sunblock, hats, sunglasses etc.). The baseline investigations for both groups will include complete blood picture (CBC), liver function tests (LFTs), renal function tests (RFTs), electrocardiogram, chest X-ray and urine analysis while thiopurine methyltransferase (TPMT) levels will be assessed specifically for group B patients. The patients will be followed up at week 4, 12 and 24. CBC, RFTs and LFTs will be done at each follow-up and EASI score will be calculated, | 2 | 7 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- 50% Reduction in the Eczema Area and Severity Index Score (EASI-50)
- Description
EASI-50 means 50% reduction in the Eczema Area and Severity Index score from baseline score. EASI is a scale used to evaluate the degree and severity of eczema. The total EASI score is between 0 and 72 .~Mild disease: Patients with a score of 1.1-7.0 on the EASI scale will be classified as having mild disease.~Moderate disease: Patients with a score of 7.1 to 21.0 on the EASI scale will be classified as having moderate disease.~Severe disease: Patients with a score of 21.1-50.0 on the EASI scale will be classified as having severe disease.~Very Severe disease: Patients with a score of 50.1-72.0 on the EASI scale will be classified as having very severe disease.
- Time frame
- 6 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial
- NCT number
- NCT06476366
- Phases
- EARLY_PHASE1
- Conditions
- Chronic Actinic Dermatitis
- Interventions
- Azathioprine, Methotrexate
- Lead sponsor
- Pak Emirates Military Hospital
- Results first posted
- 2025-08-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT06476366?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT06476366-c795886e